Company’s 36-month beta value is 0.86.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNDX is 84.18M, and currently, short sellers hold a 25.15% ratio of that floaft. The average trading volume of SNDX on May 07, 2025 was 2.05M shares.
SNDX) stock’s latest price update
Syndax Pharmaceuticals Inc (NASDAQ: SNDX)’s stock price has decreased by -21.59 compared to its previous closing price of 13.57. However, the company has seen a -22.34% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-05 that Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre – Head of IR Michael Metzger – Chief Executive Officer and Director Steve Closter – Chief Commercial Officer Neil Gallagher – President and Head of R&D Keith Goldan – Chief Financial Officer Anjali Ganguli – Chief Strategy Officer Conference Call Participants Jason Zemansky – Bank of America Ellen Horste – TD Cowen Peter Lawson – Barclays Michael Schmidt – Guggenheim David Dai – UBS Yigal Nochomovitz – Citi Kalpit Patel – B. Riley Securities Jeet Mukherjee – BTIG Salim Syed – Mizuho George Farmer – Scotiabank Operator Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call.
SNDX’s Market Performance
Syndax Pharmaceuticals Inc (SNDX) has experienced a -22.34% fall in stock performance for the past week, with a -5.42% drop in the past month, and a -26.16% drop in the past quarter. The volatility ratio for the week is 8.98%, and the volatility levels for the past 30 days are at 8.80% for SNDX. The simple moving average for the last 20 days is -13.65% for SNDX stock, with a simple moving average of -35.07% for the last 200 days.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with UBS repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to UBS is $37 based on the research report published on October 24, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $37. The rating they have provided for SNDX stocks is “Buy” according to the report published on June 28th, 2024.
Scotiabank gave a rating of “Sector Perform” to SNDX, setting the target price at $23 in the report published on January 31st of the previous year.
SNDX Trading at -18.22% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.56% of loss for the given period.
Volatility was left at 8.80%, however, over the last 30 days, the volatility rate increased by 8.98%, as shares sank -3.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.10% lower at present.
During the last 5 trading sessions, SNDX fell by -22.34%, which changed the moving average for the period of 200-days by -54.18% in comparison to the 20-day moving average, which settled at $12.32. In addition, Syndax Pharmaceuticals Inc saw -19.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Metzger Michael A, who sale 7,814 shares at the price of $15.05 back on Mar 04 ’25. After this action, Metzger Michael A now owns 300,121 shares of Syndax Pharmaceuticals Inc, valued at $117,564 using the latest closing price.
MICHAEL METZGER, the Officer of Syndax Pharmaceuticals Inc, proposed sale 13,888 shares at $15.48 during a trade that took place back on Mar 04 ’25, which means that MICHAEL METZGER is holding shares at $214,986 based on the most recent closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -7.87 for the present operating margin
- -0.03 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -7.58. The total capital return value is set at -0.63. Equity return is now at value -93.70, with -55.96 for asset returns.
Currently, EBITDA for the company is -313.82 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 17.42. The receivables turnover for the company is 2.78for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.80.
Conclusion
In a nutshell, Syndax Pharmaceuticals Inc (SNDX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
